Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Sponsor: Perceive Biotherapeutics, Inc.
Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Official title: Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-06-21
Completion Date
2028-03
Last Updated
2025-10-15
Healthy Volunteers
No
Interventions
VOY-101
VOY-101
Locations (11)
Retina Macula Institute of AZ
Scottsdale, Arizona, United States
The Retina Partners
Encino, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Retina Consultants San Diego
San Diego, California, United States
Star Retina
Burleson, Texas, United States
Retina Center of Texas
Southlake, Texas, United States
University of Utah John A. Moran Eye Center
Salt Lake City, Utah, United States
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Rambam Medical Center
Haifa, Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, Israel